Voglibose

Voglibose, a brand name for a formulation containing essential Voglibose, is widely used for various health benefits. This guide provides comprehensive information on the uses, dosage, side effects, and mechanism of action of Voglibose, as well as insights into how long it takes to work. Understanding these aspects can help you make informed decisions about its use and effectiveness.

Introduction

Voglibose is an anti-diabetic drug used for the management of diabetes type 2. Voglibose is a glucose derivative that works as a starch-blocking agent, which helps by reducing the postprandial glucose level through decreasing the digested carbohydrate intake by decreasing its absorption in small intestine. It belongs to the class of oral anti-diabteic drugs.

Uses For

Voglibose is primarily used for the management of hyperglycemia (high blood sugar) in type 2 diabetes. It is used for controlling blood sugar levels after meals, thereby reducing the risk of long-term effects associated with diabetes, such as nerve, kidney and eye damage.

Mechanism of Action

Voglibose works as a starch-blocking agent that binds to the alpha-glucosidase enzyme, which is responsible for the digestion of starchy food particles like starch. This inhibition of the alpha-glucosidase enzyme helps by preventing the digestion of carbohydrates, thereby decreasing the blood sugar levels after the meal.

How Long Does It Take To Work?

It usually takes about 2 to 3 hours after consumption of Voglibose for it to take effect and show results in lowering the blood sugar levels.

Absorption

Voglibose is rapidly absorbed from the small intestine and reaches peak plasma levels 2 to 3 hours after administration.

Route of Elimination

Voglibose is excreted mainly in the urine through glomerular filtration as unchanged Voglibose, with a very small amount being metabolized by the liver.

Dosage

The usual dosage of Voglibose for adults is 0.2-0.3 mg/kg body weight per day divided into 3 or 4 doses. For children, the usual dosage is 0.05-0.1 mg/kg body weight per day divided into 3 or 4 doses.

Administration

Voglibose is usually administered orally with or without food for adults and children, as directed by the physician.

Side Effects

The most common side effects of Voglibose are abdominal discomfort, flatulence, diarrhea, nausea, and vomiting. Rare side effects include headache, dizziness, and flushed skin.

Toxicity

Voglibose is a very safe drug and is very unlikely to cause any serious toxicity even at very high doses.

Precaution

Voglibose should be taken as prescribed by the physician with appropriate diet and exercise. It should be used with caution in geriatric patients, pregnant women, and breastfeeding mothers. It should not be used in patients who are sensitive to Voglibose or any of its components.

Interactions

Voglibose can interact with other medications such as insulin andalpha-glucosidase inhibitors. Therefore, it should not be used in combination with these drugs unless prescribed by the physician. It may also interact with certain herbal products, so it is recommended to check with the physician before taking any other medications.

Disease Interactions

Voglibose should be used with caution in patients with pre-existing cardiovascular disease, renal or hepatic diseases, and in those with underlying metabolic disorders such as lactic acidosis or ketoacidosis.

Drug Interactions

Voglibose may interact with some drugs such as insulin, thiazide diuretics, metformin, sulfonylureas, angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). Therefore, it is recommended to check with the physician before taking any other medications.

Food Interactions

Certain food items may interact with Voglibose and alter its effectiveness, such as beer, wine, bourbon, and other alcoholic beverages. Therefore, it is recommended to avoid taking these food items while taking Voglibose.

Pregnancy Use

Voglibose should be used with caution in pregnant women. It is recommended to consult with the physician before taking Voglibose during pregnancy.

Lactation Use

Voglibose should not be used duringbreastfeeding as it may pass into breast milk and cause serious harm to the baby. It is recommended to consult with the physician before taking Voglibose during breastfeeding.

Acute Overdose

In case of acute overdose, seek immediate medical attention as it can lead to serious adverse effects such as hypoglycemia, lactic acidosis, and ketoacidosis.

Contraindication

Voglibose is contraindicated in patients who are hypersensitive to Voglibose or any of its components.

Use Direction

Voglibose should be taken exactly as prescribed by the physician. It should be taken orally with or without food. The usual dosage for adults is 0.2-0.3 mg/kg body weight per day divided into 3 or 4 doses.

Storage Condition

Voglibose should be stored at room temperature away from direct heat and sunlight. It should be kept in an air-tight container and away from children.

Volume of Distribution

The volume of distribution of Voglibose is unknown.

Half Life

The half-life of Voglibose is 2 to 3 hours.

Clearance

The clearance of Voglibose is unknown.

Here you find in details version of Voglibose

https://www.medicinesfaq.com/brand/voglibose, http://classyfire.wishartlab.com/tax_nodes/C0000000, http://classyfire.wishartlab.com/tax_nodes/C0004603, http://classyfire.wishartlab.com/tax_nodes/C0000323, http://classyfire.wishartlab.com/tax_nodes/C0000129, http://classyfire.wishartlab.com/tax_nodes/C0004343, http://classyfire.wishartlab.com/tax_nodes/C0002674, http://classyfire.wishartlab.com/tax_nodes/C0002647, http://classyfire.wishartlab.com/tax_nodes/C0001670, http://classyfire.wishartlab.com/tax_nodes/C0001897, http://classyfire.wishartlab.com/tax_nodes/C0002286, http://classyfire.wishartlab.com/tax_nodes/C0002228, http://classyfire.wishartlab.com/tax_nodes/C0000286, http://classyfire.wishartlab.com/tax_nodes/C0004557, http://classyfire.wishartlab.com/tax_nodes/C0004150, http://www.hmdb.ca/metabolites/HMDB0015598, http://www.genome.jp/dbget-bin/www_bget?drug:D01665, https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=444020, https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504462, https://www.chemspider.com/Chemical-Structure.392046.html, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50263044, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=32300, https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL476960, https://zinc.docking.org/substances/ZINC000003788703, http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001104, http://www.pharmgkb.org/drug/PA164752433, https://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VOG, https://en.wikipedia.org/wiki/Voglibose,